News

The quest for a respiratory syncytial virus vaccine is almost complete

After tragedy struck during a 1960s clinical trial, development of a vaccine for RSV ground to a halt. But as new RSV vaccine candidates enter late-stage clinical trials, a safe and effective vaccine is finally in sight.
Written byStephanie DeMarco, PhD
| 8 min read
A baby girl sits in a hospital room wearing a mask as an adult places a hand on her head.

Respiratory syncytial virus can cause severe lower respiratory tract diseases in infants and older adults.

iStock/graphixchon

By the time most children turn two, they’ve likely had a respiratory syncytial virus (RSV) infection. While most children and adults who catch the virus generally experience typical cold symptoms, young infants, older adults, or immunocompromised people can get a severe RSV infection that may lead to a serious lower respiratory tract infection like pneumonia or bronchiolitis.

Jay Kolls (pictured), Fernando Polack, and their teams analyzed 50-year-old samples to understand the molecular drivers of enhanced RSV disease.
Credit: Tulane University

RSV is one of the leading causes of hospitalization in young children, with approximately 3.2 million children under five hospitalized with RSV globally, resulting in 59,600 deaths (1). Researchers estimate that approximately 336,000 adults over 60 years old are hospitalized with a severe RSV infection every year, with an associated 14,000 deaths (2).

Like the yearly flu, RSV is seasonal. It generally peaks in autumn and ends in the spring, but unlike other viruses, prior RSV infection does not lead to long-lasting immunity.

“Depending on how long the season goes, you can get infected in November and get infected again in February. That's how short lived the immunity is,” said Jay Kolls, a pediatric pulmonologist at Tulane University.

Researchers began working on an RSV vaccine in the 1960s, but when two children in a 1967 vaccine trial died (3), RSV vaccine progress halted for decades. Now with a deeper understanding of RSV biology and its interaction with the human immune system, multiple pharmaceutical companies have RSV vaccines in late-stage trials, racing to give the world its first vaccine for RSV.

A Promising Vaccine Turns Tragic

In the late 1960s, scientists at the National Institutes of Health thought that they had found the key to preventing RSV infections. They developed a formalin-inactivated vaccine against RSV (FIRSV), hoping that it would protect children who had never been exposed to RSV, but the trial results caught them completely by surprise.

“The kids who got RSV after the vaccine actually had worse disease than the kids who got the virus without any previous vaccination,” said Christine Shaw, the vice president of Early-Development Programs in Infectious Diseases at Moderna. “It actually enhanced disease instead of protecting against the pathogen.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Stephanie DeMarco, PhD Headshot

    Stephanie joined Drug Discovery News as an Assistant Editor in 2021. She earned her PhD from the University of California Los Angeles in 2019 and has written for Discover Magazine, Quanta Magazine, and the Los Angeles Times. As an assistant editor at DDN, she writes about how microbes influence health to how art can change the brain. When not writing, Stephanie enjoys tap dancing and perfecting her pasta carbonara recipe.

    View Full Profile

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.